éå»1ã¶æéã«Spero Therapeutics Incã«å¯ŸããŠè©äŸ¡ãåºããã¢ããªã¹ã1åã«åºã¥ãããŒã¿ã
仿ãSPROã¯0ä»¶ã®ãè²·ããã1ä»¶ã®ãäžç«ïŒããŒã«ãïŒãã0ä»¶ã®ã売ããè©äŸ¡ãç²åŸããŸãããçŽè¿1ã¶æã«ãããSPROã®ã¢ããªã¹ãå¹³åç®æšæ ªäŸ¡ã¯4.000ã§ãã
ã¢ããªã¹ãäºæ³ã«ãããšãFY2026Q2ã«çºè¡šãããEPS -0.165ã«ç¶ããSPROã®FY2026Q3ã®EPSã¯-0.160ã«éããèŠéãã§ããçºè¡šãããå®çžŸå€ãšäºæ³ãæ¯èŒããŠãåçæ§ã®æšç§»ã確èªããŸãããã
åžå Žäºæ³ã¯ USD -0.16 ã§ããããSpero Therapeutics IncSPRO ã®åååæã®äžæ ªåœããå©ç (EPS) 㯠USD -0.13 ã§ãããæ¬¡ã®ååæã® EPS 㯠USD -0.16 ãšäºæ³ãããŸãã